Profile data is unavailable for this security.
About the company
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.
- Revenue in USD (TTM)141.46m
- Net income in USD-72.50m
- Incorporated2014
- Employees449.00
- LocationAdaptimmune Therapeutics PLC60 Jubilee Avenue, Milton ParkABINGDON OX14 4RXUnited KingdomGBR
- Phone+44 123 543 0000
- Websitehttps://www.adaptimmune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compass Therapeutics Inc. | 850.00k | -47.24m | 238.03m | 32.00 | -- | 1.63 | -- | 280.03 | -0.3573 | -0.3573 | 0.0064 | 1.06 | 0.0051 | -- | -- | 26,562.50 | -28.22 | -41.75 | -29.94 | -46.41 | -- | -- | -5,557.88 | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Enanta Pharmaceuticals Inc | 71.96m | -115.33m | 239.43m | 145.00 | -- | 1.61 | -- | 3.33 | -5.46 | -5.46 | 3.41 | 7.03 | 0.161 | -- | 5.32 | 496,275.90 | -25.80 | -14.56 | -30.05 | -15.62 | -- | -- | -160.27 | -54.96 | -- | -- | 0.0095 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| XBiotech Inc | 0.00 | -35.01m | 242.18m | 94.00 | -- | 1.23 | -- | -- | -1.15 | -1.15 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -15.53 | 31.88 | -16.32 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0484 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Amarin Corporation plc (ADR) | 264.78m | -33.52m | 245.95m | 275.00 | -- | 0.4459 | -- | 0.9289 | -0.082 | -0.082 | 0.6466 | 1.34 | 0.319 | 0.4395 | 2.15 | 962,832.80 | -4.04 | -4.48 | -5.79 | -6.54 | 61.29 | 75.70 | -12.66 | -8.59 | 2.01 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Candel Therapeutics Inc | 0.00 | -49.99m | 246.41m | 42.00 | -- | -- | -- | -- | -1.70 | -1.70 | 0.00 | -0.321 | 0.00 | -- | -- | 0.00 | -117.35 | -- | -158.61 | -- | -- | -- | -- | -- | -- | -32.70 | 2.36 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Rezolute Inc | 0.00 | -58.21m | 247.66m | 51.00 | -- | 2.73 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| 2Seventy Bio Inc | 44.12m | -156.25m | 250.79m | 274.00 | -- | 1.07 | -- | 5.68 | -3.06 | -3.06 | 0.8417 | 4.56 | 0.0721 | -- | 1.42 | 161,021.90 | -25.54 | -- | -28.17 | -- | 66.39 | 91.76 | -354.16 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Abeona Therapeutics Inc | 0.00 | -52.60m | 251.22m | 84.00 | -- | 3.30 | -- | -- | -2.13 | -2.13 | 0.00 | 1.76 | 0.00 | -- | -- | 0.00 | -56.09 | -53.22 | -65.23 | -65.81 | -- | -- | -- | -1,894.25 | -- | -- | 0.2004 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Trevi Therapeutics Inc | 0.00 | -38.77m | 254.07m | 25.00 | -- | 3.84 | -- | -- | -0.3879 | -0.3879 | 0.00 | 0.9116 | 0.00 | -- | -- | 0.00 | -44.37 | -47.39 | -47.48 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0014 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Adaptimmune Therapeutics PLC - ADR | 141.46m | -72.50m | 258.30m | 449.00 | -- | 2.68 | -- | 1.83 | -0.3452 | -0.3452 | 0.5922 | 0.3765 | 0.4256 | -- | 53.33 | 315,053.40 | -21.81 | -41.19 | -28.63 | -48.21 | -- | -- | -51.25 | -714.26 | -- | -- | 0.2058 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| Mersana Therapeutics Inc | 29.94m | -104.77m | 268.66m | 123.00 | -- | 31.88 | -- | 8.97 | -0.8648 | -0.8648 | 0.2469 | 0.0687 | 0.1222 | -- | 38.14 | 243,390.30 | -42.75 | -61.68 | -59.36 | -81.35 | -- | -- | -349.98 | -622.19 | -- | -- | 0.7508 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Black Diamond Therapeutics Inc | 0.00 | -80.55m | 270.09m | 54.00 | -- | 2.43 | -- | -- | -1.54 | -1.54 | 0.00 | 1.97 | 0.00 | -- | -- | 0.00 | -59.70 | -40.29 | -67.82 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Vanda Pharmaceuticals Inc. | 182.02m | -10.93m | 271.05m | 203.00 | -- | 0.4996 | -- | 1.49 | -0.1886 | -0.1886 | 3.15 | 9.31 | 0.2815 | 9.96 | 4.82 | 896,660.10 | -1.69 | 6.61 | -1.97 | 7.62 | 93.03 | 90.55 | -6.00 | 15.18 | 4.67 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Zura Bio Ltd | 0.00 | -27.94m | 274.23m | 14.00 | -- | 1.75 | -- | -- | -0.4944 | -0.4944 | 0.00 | 2.46 | 0.00 | -- | -- | 0.00 | -23.00 | -- | -30.30 | -- | -- | -- | -- | -- | -- | -- | 0.0136 | -- | -- | -- | -2,050.99 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Adaptimmune Therapeutics PLC's reporting currency: US Dollar USD
45.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Matrix Capital Management Co. LPas of 30 Jun 2024 | 38.97m | 15.24% |
| EcoR1 Capital, LLCas of 30 Jun 2024 | 27.40m | 10.72% |
| Baillie Gifford & Co.as of 30 Jun 2024 | 15.15m | 5.92% |
| Long Focus Capital Management LLCas of 30 Jun 2024 | 12.35m | 4.83% |
| PFM Health Sciences LPas of 30 Jun 2024 | 10.52m | 4.11% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 4.65m | 1.82% |
| Rock Springs Capital Management LPas of 30 Jun 2024 | 2.43m | 0.95% |
| Baker Bros. Advisors LPas of 30 Jun 2024 | 2.34m | 0.92% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 1.79m | 0.70% |
| Tang Capital Management LLCas of 30 Jun 2024 | 1.74m | 0.68% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
